GlassScriptPhysician profile
Richard B Whalen
NPI 1043202138
$13,685.63
in general payments reported to CMS, 2019-2025
48 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,191 · 2020: $1,266 · 2021: $1,712 · 2022: $1,897 · 2023: $2,568 · 2024: $2,061 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,594 · Education: $25.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,593.73 |
| Education | $25.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,393.01 | 2019-2025 | |
| Novo Nordisk INC | $1,383.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,272.71 | 2019-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,214.87 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $1,020.58 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Abbvie INC. | $862.47 | 2021-2025 | Vraylar, Linzess, Ubrelvy |
| Astellas Pharma US INC | $856.30 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $810.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $709.05 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $629.94 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $509.43 | 2019-2025 | Eliquis, Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $324.17 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $317.93 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $241.25 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $196.16 | 2023-2025 | Rexulti |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Whalen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.